Teva Pharmaceutical Industries Ltd. (TEVA)
39.10
-0.03
(-0.08%)
USD |
NYSE |
Oct 07, 10:17
Teva Pharmaceutical Industries EPS Diluted (Quarterly) : -0.5029 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.5029 |
| March 31, 2026 | 0.3121 |
| December 31, 2025 | 0.4118 |
| September 30, 2025 | 0.3737 |
| June 30, 2025 | 0.2481 |
| March 31, 2025 | 0.1837 |
| December 31, 2024 | -0.1931 |
| September 30, 2024 | -0.3868 |
| June 30, 2024 | -0.7438 |
| March 31, 2024 | -0.1252 |
| December 31, 2023 | 0.4098 |
| September 30, 2023 | 0.0606 |
| June 30, 2023 | -0.7694 |
| March 31, 2023 | -0.1955 |
| December 31, 2022 | -1.168 |
| September 30, 2022 | 0.0496 |
| June 30, 2022 | -0.2066 |
| March 31, 2022 | -0.8646 |
| December 31, 2021 | -0.1448 |
| September 30, 2021 | 0.2645 |
| June 30, 2021 | 0.1873 |
| March 31, 2021 | 0.0688 |
| December 31, 2020 | 0.1375 |
| September 30, 2020 | -3.998 |
| June 30, 2020 | 0.1285 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.0631 |
| December 31, 2019 | 0.1009 |
| September 30, 2019 | -0.2895 |
| June 30, 2019 | -0.6302 |
| March 31, 2019 | -0.0967 |
| December 31, 2018 | -2.832 |
| September 30, 2018 | -0.268 |
| June 30, 2018 | -0.2348 |
| March 31, 2018 | 1.033 |
| December 31, 2017 | -11.46 |
| September 30, 2017 | 0.5215 |
| June 30, 2017 | -6.000 |
| March 31, 2017 | 0.578 |
| December 31, 2016 | -1.017 |
| September 30, 2016 | 0.3521 |
| June 30, 2016 | 0.2002 |
| March 31, 2016 | 0.6258 |
| December 31, 2015 | 0.5505 |
| September 30, 2015 | 0.1192 |
| June 30, 2015 | 0.6359 |
| March 31, 2015 | 0.5179 |
| December 31, 2014 | 0.7935 |
| September 30, 2014 | 1.009 |
| June 30, 2014 | 0.8724 |
| March 31, 2014 | 0.8691 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Eli Lilly & Co. | 7.939 |
| Bristol Myers Squibb Co. | 1.620 |
| Merck & Co., Inc. | -0.5405 |
| RedHill Biopharma Ltd. | -- |
| Johnson & Johnson | 2.268 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -585.89M |
| Revenue (Quarterly) | 4.221B |
| Total Expenses (Quarterly) | 4.807B |
| Enterprise Value | 58.81B |
| Gross Profit Margin (Quarterly) | 52.07% |
| Profit Margin (Quarterly) | -13.88% |
| Earnings Yield | 1.52% |
| Operating Earnings Yield | 7.17% |
| Normalized Earnings Yield | 4.060 |